GlassScriptPhysician profile
Stephen M Neff
NPI 1710041496
$2,413.40
in general payments reported to CMS, 2019-2025
17 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $59.74 · 2023: $1,584 · 2024: $243 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,204 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $805 · Consulting Fee: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,203.66 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $805.00 |
| Consulting Fee | $345.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $1,499.93 | 2022-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $218.47 | 2024-2025 | Caplyta |
| Collegium Pharmaceutical, INC. | $110.37 | 2025 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $89.01 | 2023-2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $71.13 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $68.11 | 2023-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $57.63 | 2023-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $54.81 | 2025 | Spravato |
| Noven Therapeutics, LLC | $45.21 | 2024 | Xelstrym |
| Neos Therapeutics, LP | $44.03 | 2023 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $31.87 | 2022-2023 | Quviviq |
| Bausch Health US, LLC | $30.58 | 2023 | Aplenzin, Wellbutrin |
| Takeda Pharmaceuticals U.S.A., INC. | $29.30 | 2022 | |
| Alkermes, INC. | $17.46 | 2023 | Aristada, Lybalvi |
| Abbvie INC. | $16.86 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $14.82 | 2025 | Relexxii |
| Almatica Pharma LLC | $13.81 | 2025 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Neff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.